Social contextual factors associated with entry into opiate agonist treatment among injection drug users

American Journal of Drug and Alcohol Abuse

Volumn 31, Issue 4, 2005, Pages 555-570

  Lloyd, Jacqueline J ^a   Ricketts, Erin P ^b   Strathdee, Steffanie A ^b,c   Cornelius, Llewellyn J ^d   Bishai, David ^b   Huettner, Steven ^b   Havens, Jennifer R ^e   Latkin, Carl ^b  

^a TEMPLE UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Injection drug users; Living arrangement; Social network; Treatment

Indexed keywords

LEVACETYLMETHADOL; OPIATE AGONIST;

ADDICTION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; ENVIRONMENTAL FACTOR; FAMILY; FEMALE; HEALTH PROGRAM; HOMELESSNESS; HOUSING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOCIAL ASPECT; SOCIAL ENVIRONMENT;

ADULT; FEMALE; HIV INFECTIONS; HUMANS; MALE; METHADONE; NARCOTICS; NEEDLE-EXCHANGE PROGRAMS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SOCIAL SUPPORT; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 27944453903     PISSN: 00952990     EISSN: None     Source Type: Journal    
DOI: 10.1081/ADA-200068114     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, CDC, 2000; 12(1).
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report: Cases of HIV Infection and AIDS in the United States. Vol. 14. Atlanta, GA: U.S. Department of Health and Human Services, 2002.
3. Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep 1998; 113(suppl 1):75-80.
4. Spijkerman IJ, van Ameijden EJ, Mientjes GH, Coutinho RA, van den Hoek A. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol 1996; 49(10):1149-1154.
5. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, DePhilippis D, Stolley P, Abrutyn E. Human immunodeficiency virus seorconversion among intravenous drug users in-and out-of treatment: an 18 month prospective follow-up. J Acquir Immune Defic Syndr 1993; 6(9):1049-1056.
6. Yancovitz SR, Des Jarlais DC, Peyser NP, Drew E, Friedmann P, Trigg HL, Robinson JW. A randomized trial of an interim methadone maintenance clinic. Am J Public Health 1991; 81(9):1185-1191.
7. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York: Springer Verlag, 1991.
8. Institute of Medicine. Treating Drug Problems, Vol. 1: A Study of the Evolution, Effectiveness, and Financing of Public and Private Drug Treatment Systems. Washington, DC: National Academy Press, 1990.
9. Camacho LM, Bartholowmew NG, Joe GW, Simpson DD. Maintenance of HIV risk reduction among injection opioid users: a 12-month post-treatment follow-up. Drug Alcohol Depend 1997; 47(1):11-18.
10. Watkins KE, Metzger D, Woody G, McLellan AT. High-risk sexual behaviors of intravenous drug users in-and out-of treatment: implications for the spread of HIV infection. Am J Drug Alcohol Abuse 1992; 18(4):389-398.
11. Friedman SR, Jose B, Deren S, Des Jarlais D, Neaigus A. Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. The National Aids Research Consortium. Am J Epidemiol 1995; 142(8):864-874.
12. Moss AR, Vranizan K, Goiter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 1994; 8(2):223-231.
13. COMPA, (New York State Committee of Methadone Program Administrators, Inc.). Regarding Methadone Treatment: A Review. Vol. 6. New York, 1997:9-10.
14. Schutz CG, Rapid E, Vlahov D, Anthony JC. Suspected determinants of enrollment into detoxification and methadone maintenance treatment among injection drug users. Alcohol Drug Depend 1994; 36(2):129-138.
15. American Methadone Treatment Association. 1998 Methadone Maintenance Program and Patient Census in the U.S., New York: American Association for the Treatment of Opioid Dependence, April 1999.
16. Centers for Disease Control and Prevention. Risk behaviors for HIV transmission among intravenous drug users not in treatment-United States. MMWR 1990; 39(16):273-276.
17. Schutz CG, Rapiti E, Vlahov D, Anthony JC. Suspected determinants of enrollment into detoxification and methadone maintenance treatment among injection drug users. Alcohol Drug Depend 1994; 36(2):129-138.
18. Shah NG, Celentano DD, Vlahov D, Stambolis V, Johnson L, Nelson KE, Strathdee SA. Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. AIDS 2000; 14(13):2035-2043.
19. Riley ED, Safaeian M, Strathdee SA, Brooner RK, Beilenson P, Vlahov D. Drug user treatment referrals and entry among participants of a needle exchange program. Subst Use Misuse 2002; 37(14):1869-1886.
20. Zule WA, Desmond DP. Factors predicting entry of injecting drug users into substance abuse treatment. Am J Drug Alcohol Abuse 2000; 26(2):247-261.
21. Booth RE, Corsi KF, Mikulich SK. Improving entry into methadone maintenance among out-of-treatment injection drug users. J Subst Abuse Treat 2003; 24(4):305-311.
22. Goehl L, Nunes E, Quitkin F, Hilton I. Social networks and methadone treatment outcome: the costs and benefits of social ties. Am J Drug Alcohol Abuse 1993; 19(3):251-262.
23. Gogineni A, Stein MD, Friedmann PD. Social relationships and intravenous drug use among methadone maintenance patients. Drug Alcohol Depend 2001; 64(1):47-53.
24. Westreich L, Heitner C, Cooper M, Galanter M, Guedj P. Perceived social support and treatment retention on an inpatient addiction treatment unit. Am J Addict 1997; 6(2):144-149.
25. Tuten M, Jones HE. A partner's drug-using status impacts women's drug treatment outcome. Drug Alcohol Depend 2003; 70(3):327-330.
26. Lundgren LM, Schilling RF, Fitzgerald T, Davis K, Amodeo M. Parental status of women injection users and entry to methadone maintenance. Subst Use Misuse 2003; 38(8):1109-1131.
27. Appel PW, Ellison AA, Jansky HK, Oldak R. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: opinions of drug injecting street outreach clients and other system stakeholders. Am J Drug Alcohol Abuse 2004; 30(1):129-153.
28. Vlahov D, Junge B, Brookmeyer R, Cohn S, Riley E, Armenian H, Beilenson P. Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. J Acquir Immune Defic Syndr Human Retrovirol 1997; 16(5):400-406.
29. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9(3):199-213.
30. Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series, Number 1. DHHS Pub. No. (SMA) 93-1991. Washington, DC: U.S. Government Printing Office, 1993.
31. Dobkin PL, De CM, Paraherakis A, Gill K. The role of functional social support in treatment retention and outcomes among outpatient adult substance abusers. Addiction 2002; 97(3):347-356.
32. Kline A. Pathways into drug user treatment: the influence of gender and racial/ethnic identity. Subst Use Misuse 1996; 31(3):323-342.